Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LBT Innovations Limited ( (AU:CC5) ) has issued an announcement.
Clever Culture Systems Ltd, a leader in AI microbiology automation, presented at its 2025 Annual General Meeting, highlighting its innovative technology, the APAS Independence. This system, which automates the analysis of microbiology culture plates, is the only US FDA-cleared AI technology for this purpose and is distributed by Thermo Fisher Scientific in the US and Europe. The announcement underscores CCS’s strong market position in microbiology automation and its impact on pharmaceutical manufacturing and clinical diagnostics.
More about LBT Innovations Limited
Clever Culture Systems (CCS) is a leader in AI microbiology automation, providing intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the company has developed the Automated Plate Assessment System (APAS Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI technology for automated culture plate reading, and it is sold to microbiology laboratories in the pharmaceutical manufacturing sector and clinical laboratories for infectious disease diagnostics. Thermo Fisher Scientific, Inc is the exclusive distributor of the APAS Independence to clinical customers in the United States and selected European countries.
Average Trading Volume: 1,952,823
Technical Sentiment Signal: Hold
Current Market Cap: A$65.67M
For a thorough assessment of CC5 stock, go to TipRanks’ Stock Analysis page.